scholarly journals From predictions to prescriptions: A data-driven response to COVID-19

Author(s):  
Dimitris Bertsimas ◽  
Leonard Boussioux ◽  
Ryan Cory-Wright ◽  
Arthur Delarue ◽  
Vasileios Digalakis ◽  
...  

The COVID-19 pandemic has created unprecedented challenges worldwide. Strained healthcare providers make difficult decisions on patient triage, treatment and care management on a daily basis. Policy makers have imposed social distancing measures to slow the disease, at a steep economic price. We design analytical tools to support these decisions and combat the pandemic. Specifically, we propose a comprehensive data-driven approach to understand the clinical characteristics of COVID-19, predict its mortality, forecast its evolution, and ultimately alleviate its impact. By leveraging cohort-level clinical data, patient-level hospital data, and census-level epidemiological data, we develop an integrated four-step approach, combining descriptive, predictive and prescriptive analytics. First, we aggregate hundreds of clinical studies into the most comprehensive database on COVID-19 to paint a new macroscopic picture of the disease. Second, we build personalized calculators to predict the risk of infection and mortality as a function of demographics, symptoms, comorbidities, and lab values. Third, we develop a novel epidemiological model to project the pandemic’s spread and inform social distancing policies. Fourth, we propose an optimization model to reallocate ventilators and alleviate shortages. Our results have been used at the clinical level by several hospitals to triage patients, guide care management, plan ICU capacity, and re-distribute ventilators. At the policy level, they are currently supporting safe back-to-work policies at a major institution and equitable vaccine distribution planning at a major pharmaceutical company, and have been integrated into the US Center for Disease Control’s pandemic forecast.Significance StatementIn the midst of the COVID-19 pandemic, healthcare providers and policy makers are wrestling with unprecedented challenges. How to treat COVID-19 patients with equipment shortages? How to allocate resources to combat the disease? How to plan for the next stages of the pandemic? We present a data-driven approach to tackle these challenges. We gather comprehensive data from various sources, including clinical studies, electronic medical records, and census reports. We develop algorithms to understand the disease, predict its mortality, forecast its spread, inform social distancing policies, and re-distribute critical equipment. These algorithms provide decision support tools that have been deployed on our publicly available website, and are actively used by hospitals, companies, and policy makers around the globe.

2016 ◽  
Vol 82 ◽  
pp. 1-7 ◽  
Author(s):  
Breno Satler Diniz ◽  
Chien-Wei Lin ◽  
Etienne Sibille ◽  
George Tseng ◽  
Francis Lotrich ◽  
...  

Author(s):  
C. Barger ◽  
J. Fockler ◽  
W. Kwang ◽  
S. Moore ◽  
D. Flenniken ◽  
...  

Background: Effective and measurable participant recruitment methods are urgently needed for clinical studies in Alzheimer’s disease. Objectives: To develop methods for measuring recruitment tactics and evaluating effectiveness. Methods: Recruitment tactics for the Alzheimer’s Disease Neuroimaging Initiative (ADNI3) were measured using web and phone analytics, campaign metrics and survey responses. Results: A total of 462 new participants were enrolled into ADNI3 through recruitment efforts. We collected metrics on recruitment activities including 82,003 unique visitors to the recruitment website and 3,335 calls to study phone numbers. The recruitment sources that produced the most screening and enrollment included online advertisements, local radio and newspaper coverage and emails and referrals from registries. Conclusions: Analysis of recruitment activity obtained through tracking methods provided some insight for effective recruitment. ADNI3 can serve as an example of how a data-driven approach to centralized participant recruitment can be utilized to facilitate clinical research.


2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Rodrigo R. R. Duarte ◽  
Dennis C. Copertino ◽  
Luis P. Iñiguez ◽  
Jez L. Marston ◽  
Yaron Bram ◽  
...  

Abstract Background Vaccination programs have been launched worldwide to halt the spread of COVID-19. However, the identification of existing, safe compounds with combined treatment and prophylactic properties would be beneficial to individuals who are waiting to be vaccinated, particularly in less economically developed countries, where vaccine availability may be initially limited. Methods We used a data-driven approach, combining results from the screening of a large transcriptomic database (L1000) and molecular docking analyses, with in vitro tests using a lung organoid model of SARS-CoV-2 entry, to identify drugs with putative multimodal properties against COVID-19. Results Out of thousands of FDA-approved drugs considered, we observed that atorvastatin was the most promising candidate, as its effects negatively correlated with the transcriptional changes associated with infection. Atorvastatin was further predicted to bind to SARS-CoV-2’s main protease and RNA-dependent RNA polymerase, and was shown to inhibit viral entry in our lung organoid model. Conclusions Small clinical studies reported that general statin use, and specifically, atorvastatin use, are associated with protective effects against COVID-19. Our study corroborrates these findings and supports the investigation of atorvastatin in larger clinical studies. Ultimately, our framework demonstrates one promising way to fast-track the identification of compounds for COVID-19, which could similarly be applied when tackling future pandemics.


2012 ◽  
Author(s):  
Michael Ghil ◽  
Mickael D. Chekroun ◽  
Dmitri Kondrashov ◽  
Michael K. Tippett ◽  
Andrew Robertson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document